Sun X-Juan, Zhang Z-Yuan, Wang S-Yi, Gittens S A, Jiang X-Quan, Chou L Lee
Department of Oral and Maxillofacial Surgery, School of Stomatology, Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Clin Oral Implants Res. 2008 Aug;19(8):804-13. doi: 10.1111/j.1600-0501.2008.01577.x.
To evaluate the effects of maxillary sinus floor elevation by a tissue-engineered bone complex with OsteoBone(trade mark) and bone marrow stromal cells (bMSCs) in rabbits.
Autologous bMSCs from adult New Zealand rabbits were cultured and combined with OsteoBone(trade mark) at a concentration of 20 x 10(6) cells/ml in vitro. Twenty-four animals were used and randomly allocated into groups. For each time point, 16 maxillary sinus floor elevation surgeries were made bilaterally in eight animals and randomly repaired by bMSCs/material (i.e. OsteoBone), material, autogenous bone and blood clot (n=4 per group). A polychrome sequential fluorescent labeling was also performed post-operatively. The animals were sacrificed 2, 4 and 8 weeks after the procedure and evaluated histologically as well as histomorphometrically.
New bone area significantly decreased from weeks 2 to 8 in the blood clot group, while bone area in the autologous bone reduced from weeks 4 to 8. In both groups, a significant amount of fatty tissue appeared at week 8. Accordingly, augmented height in both groups was also significantly decreased from weeks 2 to 8. The bone area in the material-alone group as well as in the bMSCs/material group, on the other hand, increased over time. Significantly more newly formed bone area and mineralization was observed in the center of the raised space in the bMSCs/material group than in the material-alone group. The augmented height was maintained in these two groups throughout the course of this study.
These results suggest that OsteoBone can successfully be used as a bone graft substitute and that the combination of this material with bMSCs can effectively promote new bone formation in sinus elevation.
评估含OsteoBone(商标名)和骨髓基质细胞(bMSCs)的组织工程骨复合物对兔上颌窦底提升的效果。
从成年新西兰兔获取自体bMSCs并体外培养,与OsteoBone(商标名)按20×10⁶细胞/毫升的浓度混合。使用24只动物并随机分组。在每个时间点,对8只动物双侧进行16次上颌窦底提升手术,随机用bMSCs/材料(即OsteoBone)、材料、自体骨和血凝块修复(每组n = 4)。术后还进行了多色顺序荧光标记。术后2、4和8周处死动物,进行组织学和组织形态计量学评估。
血凝块组新骨面积在术后2至8周显著减少,自体骨组骨面积在术后4至8周减少。两组在8周时均出现大量脂肪组织。相应地,两组的增高高度在术后2至8周也显著降低。另一方面,单纯材料组和bMSCs/材料组的骨面积随时间增加。与单纯材料组相比,bMSCs/材料组在提升空间中心观察到更多新形成的骨面积和矿化。在本研究过程中,这两组的增高高度得以维持。
这些结果表明,OsteoBone可成功用作骨移植替代物,且该材料与bMSCs联合可有效促进窦底提升中的新骨形成。